Atlas Of Non Fdg Pet Ct In Diagnostic Oncology

Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology. However, it has limitations in the assessment of certain tumours, above all (but not only) prostate cancer. Therefore, several non-FDG PET radiopharmaceuticals have been introduced into the clinical arena over the last few years, and this trend will continue to spread. The use of PET/CT with different PET radiopharmaceuticals that tailor to the type of tumour and biologic process that needs to be assessed is part of personalized precision medicine. The objective of this publication is to provide a case-based way of understanding normal biodistribution, variants, and pitfalls, including several examples of typical patterns for the main indications for each of the new non-FDG PET radiopharmaceuticals. This should facilitate the interpretation of images to support accurate diagnosis. This Atlas will allow professionals interested in non-FDG PET/CT imaging to embrace the variety of oncological imaging by providing clinically relevant teaching files on the effectiveness and diagnostic quality of non-FDG-PET/CT imaging in routine applications.

Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology.

This atlas is a case-based guide to the interpretation of FDG PET-CT images in clinical scenarios faced by physicians during the routine practice of oncology. The book aims to help the practitioner to overcome diagnostic dilemmas through familiarization with the physiologic distribution of FDG, normal variants and benign findings. The main focus, however, is the imaging of major oncological diseases. Different pathologies are addressed in individual chapters comprising teaching files of cases, each of which corresponds to a common indication for PET-CT imaging, such as metabolic characterization of lesions, staging, restaging and evaluation of response to therapy. Each case is accompanied by an explanation of the patient’s history, interpretation of the PET-CT study, and a teaching point often supported by relevant literature. This book will be of great value to residents and practitioners in nuclear medicine, radiology, oncology, radiation oncology and nuclear medicine technology.

The Atlas of PET/CT Imaging in Oncology serves an educational purpose and is designed to teach radiologists and nuclear medicine specialists about important aspects of molecular imaging and nuclear medicine specialists about the benefits of anatomic imaging. It consists of a brief didactic portion and an extensive selection of interesting and challenging case examples. A special feature of the atlas is an interactive CD-ROM that provides the original PET and CT images of each case in selected planes enabling the users to manually adjust the blending intensity of each modality in a fused image. In addition, users can display the clinical history, imaging techniques and diagnostic findings of each case as well as the corresponding specific teaching point.

This new atlas, the fourth of a successful series, is a completely revised and updated edition of a previously published FDG PET-CT atlas. In the past few years, considerable progress has been made in the field of PET-CT imaging, and this new edition takes full account of these recent developments. Furthermore, its educational mission has been broadened: beyond serving as a straightforward guide to FDG PET-CT imaging it now encompasses the integrative use of contrast-enhanced CT and MRI. The new edition also includes non-oncological indications for FDG PET-CT. The atlas aims to help imaging practitioners to recognize physiological and benign pathological FDG uptake and illustrates in a case-based, practical manner the PET-CT appearances of all the major tumors and infectious, inflammatory, and neurodegenerative disorders. The main clinical applications are covered, and learning points and pitfalls are clearly articulated. The consistent, user-friendly format facilitates image interpretation and allows rapid review of key information needed for FDG PET-CT imaging.

This atlas is a superb guide to the use of PET-CT for the evaluation of treatment response in oncology patients based on its ability to assess tumor metabolic status. The first part of the book explains the role of PET-CT in response evaluation in different treatment settings. For comparison, overviews of the value and limitations of CT alone, PET alone, and anatomical and functional MRI are included. Guidance is also provided on the reporting of PET-CT scans in post-therapy scenarios. The second part of the book describes and illustrates the use of PET-CT with FDG and other tracers to assess the treatment response of malignancies at different anatomic sites. Featuring a wealth of images, informative case-based discussion, and evidence-based teaching points, these disease-specific chapters clearly demonstrate the key role that PET-CT can play in distinguishing early responders from patients who are non-responders or are resistant to treatment. Prompt and accurate evaluation of treatment response is vital as we enter the era of individualized medicine, and this atlas will persuade readers of the considerable advantages of PET-CT over conventional radiological and clinical methods.

Clinical studies during the past 10 years have shown that PET is more sensitive than CT and MRI for the detection of many tumors. In many cases, however, for example in head and neck tumors, combination with radiological procedures is necessary. It may be speculated that PET should be the first study in a malignant tumor when metastatic spread is suspected. MRI and CT may then be restricted to those body areas which evince sites of increased glucose metabolism. Thus, a combination of metabolic and morphologic procedures will enhance tumor detection and change the therapeutic strategy. In this light, an atlas including PET, CT, MRI, and histology data seems desirable to combine metabolic and morphologic imaging. This book presents an overview of the available data which should be of great interest not only for specialists in radiology and nuclear medicine, but also for oncologists.

Integrated positron emission tomography/computed tomography (PET/CT) has evolved since its introduction into the commercial market more than a decade ago. It is now a key procedure, particularly in oncological imaging. Over the last years in routine clinical service, PET/CT has had a significant impact on diagnosis, treatment planning, staging, therapy, and monitoring of treatment response and has therefore played an important role in the care of cancer patients. The high sensitivity from the PET component and the specificity of the CT component give this hybrid imaging modality the unique characteristics that make PET/CT, even after over 10 years of clinical use, one of the fastest growing imaging modalities worldwide. This publication combines over 90 comprehensive cases covering all major indications of fluorodeoxyglucose (18F-FDG)-PET/CT as well as some cases of clinically relevant special tracers. The cases provide an overview of what the specific disease can look like in PET/CT, the typical pattern of the disease's spread as well as likely pitfalls and teaching points. This PET/CT Atlas will allow professionals interested in PET/CT imaging to embrace the variety of oncological imaging by providing clinically relevant teaching files on the effectiveness and diagnostic quality of FDG-PET/CT imaging in routine applications.